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Biomarkers, including cytokines, can help in the diagnosis, prognosis, and prediction of treatment response across a wide range
of disease settings. Consequently, the recent emergence of protein microarray technology, which is able to quantify a range of
inflammatorymediators in a large number of samples simultaneously, has becomehighly desirable.However, the cost of commercial
systems remains somewhat prohibitive. Here we show the development, validation, and implementation of an in-house microarray
platformwhich enables the simultaneous quantitative analysis of multiple protein biomarkers.The accuracy and precision of the in-
house microarray systemwere investigated according to the Food and Drug Administration (FDA) guidelines for pharmacokinetic
assay validation. The assay fell within these limits for all but the very low-abundant cytokines, such as interleukin- (IL-) 10.
Additionally, there were no significant differences between cytokine detection using ourmicroarray system and the “gold standard”
ELISA format. Crucially, future biomarker detection need not be limited to the 16 cytokines shown here but could be expanded as
required. In conclusion,we detail a bespoke proteinmicroarray system, utilizingwell-validated ELISA reagents, that allows accurate,
precise, and reproducible multiplexed biomarker quantification, comparable with commercial ELISA, and allowing customization
beyond that of similar commercial microarrays.
1. Introduction
A biological marker, or “biomarker,” is a quantifiable charac-
teristic that, when measured, may indicate normal biological
processes, a pathogenic state, or a pharmacological response
to a therapy [1]. As such, biomarker identification may help
to diagnose disease, aid in the prognosis of disease, and/or
help to predict treatment outcome. DNA, RNA, proteins,
cytokines, and chemokines can all act as biomarkers, sources
of which include local tissue, peripheral blood, and urine
(reviewed in [2]).
Cytokine biomarkers play an important role in a vast
range of diseases. These include but are not limited to
interferon-𝛾 (IFN-𝛾) and IFN-𝛾-induced protein 10 (IP-10) in
Mycobacterium tuberculosis, which can aid in the diagnosis of
disease, as well as vaccine-induced protection [3, 4]; CCL2 in
HIV infection, which correlates with viral load [5]; tumour
necrosis factor-𝛼 (TNF-𝛼), interleukin (IL)-1𝛽, and IL-6 in
heart failure, which are associated with more severe disease
and adverse outcome [6, 7]; and TNF-𝛼 and IL-6 in major
depressive disorder, which correlate to poor antidepressant
response [8, 9].
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The enzyme-linked immunosorbent assay (ELISA) is
the traditional method of accurately quantifying cytokine
levels. This can be performed with high sensitivity and
specificity. However, it is limited by the fact that only
one cytokine can be measured at a time [10]. However,
protein microarrays have recently evolved as a promising
tool for quantifying proteins in biological samples [11, 12]. A
protein microarray is, in many ways, a miniaturised version
of a sandwich ELISA. Quantifying cytokine abundance by
microarray typically involves printing capture antibody onto
a coated glass slide and incubating with a serum sample.
As with sandwich ELISA, target specificity is maximized
through the use of paired sets of capture and detection
antibodies, which bind to the same antigen via separate
epitopes. In contrast to ELISAs, microarrays have the ability
to evaluate multiple cytokines simultaneously. They require
smaller sample volumes than ELISAs, are more sensitive,
and have a greater dynamic range [13]. These factors make
microarrays a cheaper and potentially favourable alternative
to ELISAs for the large-scale detection of known proteins
(reviewed in [14]).
In order to utilise microarray technology, factors such
as slide surface; printing settings; print, wash, and block-
ing buffers; and detection methods must be optimised. In
addition, multiplexing requires a further optimization above
and beyond that performed for singleplex ELISAs and that
of testing for cross-reactivity between the different capture
and detection antibodies, reporter, and antigen targets. This
is typically performed in a checkerboard or matrix experi-
ment where each combination is tested as a monoplex of a
specific antigen processed against the entire panel of capture
antibodies and all detection antibodies. Following this, results
must be shown to be reproducible and be validated against
the established “gold standard,” the ELISA. As there are
currently no guidelines for protein microarray biomarker
assay development, reproducibility standards for this work
were based on the Food and Drug Administration (FDA)
guidelines for pharmacokinetic assay validation. These are
80–120% for accuracy and <20% coefficient of variation (CV)
for precision [15].
In this study, the objective was to develop and vali-
date a microarray platform to simultaneously quantify 16
biomarkers in the sera. The biomarkers were eotaxin-1,
eotaxin-2, IFN-𝛾, IL-1𝛽, IL-4, IL-6, IL-8, IL-10, IL-17, IL-
23, IP-10, monocyte chemotactic protein-1 (MCP-1), receptor
for advanced glycation end-products (RAGE), transforming
growth factor-𝛽 (TGF-𝛽), TNF-𝛼, and vascular endothelial
growth factor (VEGF). A direct comparison of ELISA and
protein microarray was performed on 30 human sera as
an integral part of the comprehensive validation of the
microarray technique.
2. Methods
2.1. Serum Samples. The University of Nottingham Medical
School Ethics Committee approved the study protocol and
written informed consent was obtained from the 30 healthy
participants before entering the study. Peripheral blood
(10mL) was collected in SST vacutainer tubes (BD); the
serum was isolated and stored at −20∘C.
2.2. Microarray Protocol. DuoSet paired antibody kits (R&D
Systems, Minneapolis, MN) were used for the detection of 16
cytokines: eotaxin-1, eotaxin-2, IFN-𝛾, IL-1𝛽, IL-4, IL-6, IL-8,
IL-10, IL-17, IL-23, IP-10, MCP-1, RAGE, TGF-𝛽, TNF-𝛼, and
VEGF. Each capture antibody diluted to 100 𝜇g/mL in PBS-
Trehalose (Dulbeccos’s phosphate buffered saline containing
50mM D-(+) Trehalose) was loaded onto a 384-well plate
(Genetix) and printed in in four sets of triplicate spots in a
16 × 16 array format onto a poly-l-lysine-coated glass slide
(Thermofisher, UK) using a Biorobotics Microgrid II arrayer
(Microgrid) and a silicon contact pin (Parallel Synthesis
Technologies, USA). During printing, the array chamber was
set to 60% humidity at 20∘C, and the spot diameter was
315 𝜇m. Printed slides were left on the arrayer overnight,
with the humidity turned off, and processed the next day.
Parameters for the optimization of the protocol presented
here are taken from Selvarajah, 2013 [16].
Slides were blocked with PBS-BSA (PBS containing 3%
BSA; Sigma) for one hour and washed three times with
PBS-Tween (PBs containing 0.05% Tween-20) wash buffer.
A cocktail of recombinant protein standards was prepared
containing each cytokine at a maximum recommended con-
centration for standard curve generation, according to man-
ufacturers instructions (R&D Systems, Minneapolis, MN).
The cocktail of standards was diluted twofold across eight
dilutions and 50 𝜇L added to each block for 45 minutes.
Slides were washed as above, and 50 𝜇L of an appropriately
diluted cocktail of biotinylated detection antibodies, each at
the manufacturers recommended concentration, was added
to each block for 45 minutes. Following another wash, 50𝜇L
of 1 : 1000 diluted streptavidin-HRP (Opti-4CN amplification
kit, #170-8238 Bio-Rad, USA) was added to each block and
slides stored in the dark for 15minutes. After further washing,
50 𝜇L of Bio-Rad amplification reagent (BAR, Opti-4CN
amplification kit) was added to each block and slides were
stored in the dark for 10 minutes. The slides were washed
three times with PBS Tween containing 20% DMSO (v/v)
and three times with wash buffer. Following this, 50𝜇L of
1 : 1000 diluted streptavidin-conjugated Cy5 (final concentra-
tion 0.2 𝜇g/mL in wash buffer: #19-4317 E-Biosciences, UK)
was added to each block and the slides were stored in the dark
for 15 minutes. After a final wash, slides were rinsed in ultra-
purewater anddried by centrifugation. Slideswere scanned at
635 nm and the data analysed using theGenePix Pro Software
(Axon GenePix). Briefly, the median local background was
subtracted from the median fluorescence of each spot and
the corrected fluorescence was used to calculate the average
fluorescence signal as well as the standard deviation. Unless
stated otherwise, all incubation stepswere performed at room
temperature. The experiment was repeated at least twice for
each biomarker.
To ascertain the accuracy of the microarray technique,
two spike-in experiments were performed for each of the
16 biomarkers at three concentrations (22 pg/mL, 188 pg/mL,
and 750 pg/mL). In the first experiment, recombinant pro-
tein standards for each of the 16 biomarkers at the above
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Figure 1: Microarray validation using spiked PBS and serum samples. (a) PBS was spiked with three known concentrations of protein:
22 pg/mL, 188 pg/mL, and 750 pg/mL. Standard curves were used to calculate the observed concentration in the PBS. Representative data
for RAGE is shown. (b) The serum protein levels of biomarkers were quantified prior (triangle) to and after (squares) the addition of three
known concentrations of cytokine (22 pg/mL, 188 pg/mL, and 750 pg/mL), bymicroarray. Standard curves were used to calculate the observed
concentration differences between the control (nonspiked) and spiked serum samples (closed bars). The three inserted horizontal lines and
numerical values in (b) indicate the difference between the quantified target level detected in control and spiked serum samples, that is, the
difference due to the addition of the spike in each case. Representative data for VEGF is shown.
concentrations were spiked into PBS, while in the second
experiment, the biomarkers were spiked into healthy donor
serum, to identify if serum proteins had any detrimental
effects on the assay system. Accuracy (%) was calculated
based on the observed concentration measured against the
expected concentration.
To determine the precision of the microarray platform,
intra- and interassay comparisons were performed for all
16 biomarkers in the sera of up to 30 healthy volunteers.
Intra-assay comparisons were performed sixteen times on
the same slide simultaneously, while interassay comparisons
were performed on different slides over a period of three
consecutive days. The mean of the replicates and standard
deviation were used to calculate the coefficients of variation
(CV) of the microarray methodology. Significant differences
between the variability of low-, mid-, and high-abundance
cytokines were determined using the Kruskal-Wallis test and
the post hoc Dunn’s multiple comparison test.
2.3. ELISA Protocol. ELISAs were performed using R&D
Systems DuoSet paired antibody kits (as per the microarray
work) according to the manufacturer’s instructions. Briefly,
plates were coated with 1–4 𝜇g/mL of capture antibody and
stored overnight. The plates were washed three times with
0.05% PBS-Tween (Sigma) and blocked with reagent diluent
(1% BSA in PBS) for one hour. Following three washes as
above, standards (prepared in reagent diluent in twofold
dilutions, according to kit instructions) were added at 100 𝜇L
per well in duplicate and the plate was incubated for two
hours. The plate was washed and incubated with 100𝜇L of
appropriately diluted biotinylated detection antibody per well
for a further two hours. After washing as above, 100 𝜇L of
diluted streptavidin-HRP was added to each well and the
plate was stored for 30 minutes in the dark. After a final
wash, the plate was developed using the enzyme substrate
peroxidase chromogen. After 30 minutes of incubation, the
reaction was stopped by adding 50𝜇L of 0.18M H
2
SO
4
per
well and the absorbance read at 450 nm. All incubations steps
were performed at room temperature.
3. Results
3.1. Microarray Validation. A microarray technique was
developed to enable the quantification of 16 cytokine
biomarkers in human sera. A series of validation tests were
performed to ensure the reproducibility and accuracy of
this technique. In the first instance, PBS (representative data
for RAGE shown in Figure 1(a)) and serum (representative
data for VEGF shown in Figure 1(b)) were spiked with
three known concentrations of protein: 22 pg/mL, 188 pg/mL,
and 750 pg/mL. The pre- and post-serum spike protein
concentrations were quantified using a protein standard
curve specific for each biomarker (Figure 1(b)). Serum was
our sample of choice over plasma, due to the consistently
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lower background signal achieved with serum, relative to
plasma for these microarrays (data not shown). BSA was
our preferred blocking buffer for all experiments; 1% I-Block
(purified casein) performs equally well (results not shown),
but BSA is preferred due to cost and ease of preparation.
The accuracy and precision values of the microarray
assay were then calculated from these data (Figure 2).
The postspike observed values for the 16 biomarkers and
expected values (dashed lines) of the biomarkers are shown
in Figures 2(a) and 2(b). All but two of the high concen-
tration spikes (750 pg/mL) were within 10% of the expected
value, whereas all of the mid- and low-concentration spikes
(22 pg/mL and 188 pg/mL) were within this range for the PBS
spike (Figure 2(a)). The same was observed for the serum
spike (Figure 2(b)). The observed mean protein values were
within the acceptable criteria of accuracy (80–120%) for the
vast majority of cytokines of the three spike concentrations
(Figures 2(c) and 2(d)). The same was true for the acceptable
level of precision (<20% CV, Figures 2(e) and 2(f)).
3.2. Microarray Limits of Detection and Quantification. The
limits of sensitivity of the assay were measured using the
lower limit of detection (LOD) and the lower and upper
limits of quantification (LLOQ and ULOQ, resp.) [17]. The
lower limit of detection (LOD) is the concentration of the
biomarker required to give a signal equal to the background
(blank) plus three times the standard deviation of the blank;
the lower limit of quantification (LLOQ) is twice the level
of the LOD or the point where the CV falls below 20%,
whichever is highest. The lower limits of detection and
quantification for the microarray assay are shown in Table 1.
For the 16 biomarkers investigated, LOD values ranged from
0.284 to 1.9 pg/mL and LLOQ values ranged from 1.5 to
5.9 pg/mL. The upper limit of quantification (ULOQ) is the
point at which the calculated precision does not exceed 15%
of the CV and the accuracy is within 15% of the expected
concentration [18] and this ranged from 750 to 1900 pg/mL
for the 16 biomarkers tested (data not shown).
3.3. Microarray Intra- and Interassay Precision. Themicroar-
ray intra- and interassay variability, using the sera of up to
30 healthy volunteers, is shown in Figure 3. Three sets of two
slides, containing 16 arrays per slide, were used for intra- and
interassay variation testing. Identical samples were used on
each set of two slides, at three independent time points. In the
case of intra-assay variation, 13 of 16 biomarkers were within
the acceptable limits of precision (<20% CV). When looking
at interassay variation, 11 out of the 16 biomarkers were within
the acceptable limits (Figure 3(a)).
The cytokine biomarkers were then subdivided into three
groups, depending on their serum abundance, and each
was analysed separately for intra- and interassay precision
(Figures 3(b) and 3(c), resp.). Low-abundance cytokines were
defined as those with a serum concentration of ≤50 pg/mL
and were IL-1𝛽, IL-4, IL-6, IL-8, IL-10, and TNF-𝛼; mid-
abundance cytokines, with a serum concentration of 51–
199 pg/mL, were eotaxin-1, IL-17, IFN-𝛾, MCP-1, TGF-𝛽, and
VEGF; and high-abundance cytokines (serum concentration
Table 1: Microarray lower limits of detection and quantification.
Biomarker Lower limit of detection(LOD) (pg/mL)
Lower limit of
quantification (LLOQ)
(pg/mL)
Eotaxin-1 1.863 2.9
Eotaxin-2 0.739 5.9
IFN-𝛾 0.108 2.9
IL-1𝛽 0.404 2.9
IL-4 0.600 2.9
IL-6 0.683 1.5
IL-8 0.535 1.5
IL-10 0.503 2.9
IL-17 0.445 5.9
IL-23 0.612 5.9
IP-10 0.458 5.9
MCP-1 0.284 5.9
RAGE 0.968 5.9
TGF-𝛽 0.398 2.9
TNF-𝛼 1.126 1.5
VEGF 0.744 1.5
The lower limit of detection (LOD) is the concentration of biomarker
required to give a signal that is equal to the background (blank) plus three
times the standard deviation of the blank. The lower limit of quantification
(LLOQ) is twice the LOD value or the point where the coefficient of variation
(CV), a measure of precision, falls below 20%, whichever is highest [17].
≥ 200 pg/mL) were eotaxin-2, IL-23, IP-10, and RAGE. The
precision values for 5 out of 6 mid-abundance cytokines and
all four high-abundance cytokines were within the acceptable
level of precision for both intra- and interassay variation.
When looking at low-abundance cytokines, however, the
median precision value for the intra-assay variation was on
the limit of acceptable precision, with 3 cytokines outside
the acceptable limit. As for the interassay variation, only one
cytokine was within the acceptable level of precision and the
median value for these low-abundance cytokines was outside
the acceptable limits of precision.
3.4. Correlation between Microarray and ELISA Cytokine
Detection Levels. The serum levels of the 16 cytokine
biomarkers were quantified from 30 healthy individuals using
both ELISA and the in-house microarray system; and the
two detection methods were compared using paired t-tests
(Figure 4) and visually represented in Bland-Altman plots
(Figure 5). There were no significant differences in the level
of cytokines detected by the two assays, for any of the
16 cytokines (P values ranged from 0.3404 to 0.997). This
highlights the agreement between the twodetectionmethods;
in concordance with this, bias in favour of either technique
was negligible (Figure 5). Furthermore, for less-abundant
cytokines, such as IL-1𝛽, the microarray platform appeared
to be slightly more sensitive than the ELISA.
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Figure 2:Microarray accuracy and precision of cytokine detection. PBS (a) and serum (b) spike experiments were performed for 16 cytokines
at three known concentrations (22 pg/mL, 188 pg/mL, and 750 pg/mL). The expected (dashed lines) and observed concentration differences
from these spiked experiments were determined by microarray. The accuracy of microarray cytokine detection was calculated for PBS (c)
and serum (d) at each spike concentration.Themajority of data fell within the acceptable limits of 80–120% accuracy, as outlined by the FDA
[15]. The precision of microarray cytokine detection in PBS (e) and serum (f) spike experiments was also calculated. Again, the majority of
data were within the limits of acceptability (<20% coefficient of variation, CV), as outlined by the FDA [15].
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Figure 3: Microarray intra- and interassay precision.The intra- and interassay precision of microarray cytokine detection was calculated (a).
Experiments to measure intra-assay precision were conducted on the same slide (𝑛 = 15 arrays), while those to measure interassay precision
were performed on three consecutive days (𝑛 = 30 arrays per time point). The median precision values for intra- and interassay variation
were within the acceptable limit of 20% coefficient of variation (CV), akin to themajority of individual cytokines. Cytokines were divided into
low-abundance (<50 pg/mL), mid-abundance (51–199 pg/mL), and high-abundance (>200 pg/mL) groups for intra- and interassay variation
((b) and (c), resp.). All high-abundance cytokines, along with all but one mid-abundance cytokine, showed acceptable levels of intra- and
interassay variation. The majority of low-abundance cytokines showed unacceptable interassay variation.
4. Discussion
Biomarkers can be very helpful in the diagnosis of disease,
aid in the prognosis of disease, and/or help to predict
treatment outcome. As a result, efforts to identify and
quantify biomarkers have increased substantially in recent
years. However, access to commercial protein microarray
platforms is expensive and makes them unattainable for
most [19]. Further adding to the problem is a lack of
comprehensive guidelines for microarray protein biomarker
validation studies. In this study, we validated our in-house
sandwich microarray according to the FDA guidelines for
pharmacokinetic assays.
Microarray spike recovery tests, performed on both PBS
and human serum, showed accuracy and precision values
of cytokine detection that were within the acceptable limits:
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Figure 4: Continued.
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Figure 4: Correlation between microarray and ELISA cytokine detection levels.The levels of 16 cytokines were quantified by microarray and
ELISA techniques in up to 30 human serum samples. Paired t-tests showed there were no significant differences between the two techniques
for any of the cytokines tested. The 16 cytokines were eotaxin-1, eotaxin-2, IFN-𝛾, IL-1𝛽, IL-4, IL-6, IL-8, IL-10, IL-17, IL-23, IP-10, MCP-1,
RAGE, TGF-𝛽, TNF-𝛼, and VEGF.
80 to 120% accuracy and <20% CV precision. This was
in accordance with published literature [20–24]. Addition-
ally, microarray intra- and interassay precision values were
deemed acceptable for nine out of ten mid- and high-
abundance cytokines, with the tenth being on the borderline
of acceptability. As might be expected, there was a greater
level of interassay variation compared to intra-assay variation
and in low-abundance cytokines, such as IL-10, compared to
mid- and high-abundance cytokines.
The limits of quantification are defined as the lowest
and highest points in an assay that can be detected and
quantified to an acceptable level of accuracy and precision.
The microarray platform proved to be superior in sensitivity
and has the advantage of detecting the lowest concentrations
of cytokines [25, 26]. Whilst the LOD shown here is very
low (less than 1 pg/mL for most of the examined cytokines),
often it is not chosen as the limit to measure proteins in
biological samples, as at this concentration there is a higher
degree of variability between samples and thus the LLOQ is
preferred when using microarray technology as the lowest
analyte concentration that can be quantified to an acceptable
level with both accuracy and precision.
Decisively, no significant differences were found between
serum cytokine levels detected by microarray and the ELISA,
the “gold standard” in immunoassays [27, 28], showing the
two techniques to be comparable. However, for some low-
abundance biomarkers, such as IL-1𝛽 and IL-6, there was less
agreement between techniques. Interestingly, this may be due
to the greater sensitivity of the microarray detection format
[26, 29]; microarray fluorescence detection is measured over
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(j) TGF-𝛽
Figure 5: Continued.
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Figure 5: Bland Altman plots to compare ELISA and microarray. The acceptable level of bias is dictated by the thin dotted line on either side
of zero.The dashed lines represent the 95% limits of agreement as the mean difference (2 SD).The differences between ELISA andmicroarray
estimations show a notable advantage of the microarray technique in sensitivity especially for the low-abundance cytokines, such as IL-1𝛽
and IL-6.
a range of many 10,000 s of fluorescence arbitrary units,
compared to the discrete 0 to 3 optical density scale available
in ELISAs.
One of our aims within this work was to produce a cost-
effective method to support multiple cytokine/chemokine
assays for large numbers of samples. With this in mind
we have estimated the cost of performing equivalent 16
cytokine assays on multiple samples, assuming best use of
reagents for commercial kits, and encompassing the number
of plates/slides and associated secondary reagents required,
but not pipette tips or technical time. Based upon this, we
estimate that R&D Duoset kits would allow testing of 712
samples for each cytokine, in duplicate, requiring 240, 96-well
plates and cost approximately £0.63 per cytokine per sample
(£10 per sample for 16 cytokines).
Based upon similar best use of the same ELISA kits,
our system would allow the testing of 2872 samples, with
4 technical replicates for each cytokine per array. Including
slide, amplification and fluorescent dye costs equate to £0.18
per cytokine tested, or £2.88 per sample. This 71% saving
comes with added technical replication, improved quality
control based upon the analysis of spot morphology within
the arrays, and reduced logistical issues due to the reduced
number of plate “equivalent” assays required (roughly 1\10th
of the number of ELISA plates are required).
The closest equivalent commercial cytokine array is a 96-
well plate array from Quantsys (testing 16 cytokines), which
costs £11.45 per sample, or £0.71 per cytokine tested. Once
again our system represents a 75% saving.
5. Conclusions
In summary, a series of experiments have been conducted
to test the performance of an in-house microarray system
in terms of accuracy, precision, and reproducibility. We
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have shown that 11 of the 16 cytokine biomarkers tested
are in line with the FDA guidelines for analytical method
validation. However, we saw a loss of precision at the lowest
concentrations of protein in ra. This highlights the require-
ment for more detailed guidelines on acceptable levels of
accuracy and precision, specifically with regard to biomarker
detection, which are standardized across research institutions
[30, 31]. This microarray system clearly offers great scope
for the detection of biomarkers using microarrays. The in-
house microarray protocol established here enables multiple
biomarkers to be quantified simultaneously with relative ease,
uses a smaller sample volume and is more sensitive than
ELISA, and has lower running costs. Importantly, detection
is not limited to the 16 biomarkers shown here but can be
expanded as required.
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